Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
2014 ◽
Vol 15
(1)
◽
pp. 78-86
◽
Keyword(s):
Phase 3
◽